As of May 2012 websites are required by law to gain your consent before applying cookies. We use cookies to improve your browsing experience. Parts of the website may not work as expected without them. By closing this message, you are consenting to our use of cookies. Close Learn more


Asthma Package


> Download your free sample > Contact us to find out more



This comprehensive coverage provides up-to-date opinions and forecasts based on extensive secondary research backed by a survey of 142 high prescribing pulmonologists and detailed discussions with KOLs.  Learn how the disease is currently treated, the unmet needs and how new market entrants (branded and generics/biosimilars) will affect the market in the future.

The Datamonitor Healthcare difference

What this package includes

Total number of physicians interviewed

US Japan France Germany Italy Spain UK
Pulmonologists 31 23 18 15 18 19 18


Coverage summary

Reports included in package
  • Epidemiology
  • Marketed drugs profiles
  • Pipeline drugs profiles
  • Treatment (physician insights)
  • Patient-based drug forecasts
Countries evaluated US, Japan, France, Germany, Italy, Spain, UK
Patient-based drug forecast period 2012–21
Patient subpopulations forecasted
  • Severity (intermittent, mild persistent, moderate persistent, severe persistent)
Drugs profiled
  • Advair
  • Asmanex
  • Breo
  • Dulera
  • Flovent
  • Flutiform
  • Pulmicort
  • Singulair
  • Symbicort
  • Xolair
  • Cinquil
  • QMF149
  • lebrikizumab
  • masitinib
  • mepolizumab



Key Findings

While inhaled corticosteroids/long-acting beta 2 agonists (ICS/LABAs) will easily remain unrivaled as the most profitable drug class in asthma, the class is expected to see significant internal changes over the forecast period. ICS/LABAs will face a significant threat as the first generics are expected to enter the market from 2014. However, despite the top two brands Advair (fluticasone/salmeterol; GlaxoSmithKline) and Symbicort (budesonide/formoterol; AstraZeneca) facing generic threat, the impact on the class’s value will be muted as greater patient switching will be seen from these brands to the first once-daily ICS/LABAs than to generics.

> Download your free sample > Contact us to find out more

Datamonitor Healthcare is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726